Work

Tumefactive demyelination in a patient with relapsing-remitting MS on ocrelizumab

Year: 2019

Type: article

Abstract: Ocrelizumab is an intravenously infused humanized monoclonal antibody that induces antibody-dependent cellular cytolysis and complement-mediated lysis of CD20-expressing B cells. Ocrelizumab reduced gadolinium-enhancing activity 94% and 95% compared with subcutaneous interferon beta-1a in relapsing-remitting MS (RRMS).1 We report a case of tumefactive demyelination (TD) in an ocrelizumab-treated patient with RRMS.

Source: Neurology Neuroimmunology & Neuroinflammation

DOI: 10.1212/nxi.0000000000000589

Authors: Vanessa F. Moreira Ferreira, David Meredith, James M. Stankiewicz

Institutions: Brigham and Women's Hospital, Harvard University

Language: English

Topic: Multiple Sclerosis Research Studies

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,450